Novartis shares slide after third clinical setback
Novartis’ U.S.-listed stock was pacing toward its steepest drop on record after the company announced its third clinical setback in a matter of days.
By Mackenzie Tatananni Novartis can't catch a break — and its stock is paying the price. -listed shares were heading toward their steepest drop on record after Novartis reported a third clinical setback in a matter of days. On Tuesday, the company said del-desiran, the centerpiece of its latest update, had suffered another setback.